This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): long-acting recombinant Factor IX, MOD-9017
Description: Factor VIIa-CTP is a longer-acting version of recombinant Factor IX that uses Carboxyl Terminal Peptide (CTP) technology. CTP is a short, naturally-occurring amino acid sequence that has the effect of slowing the removal/breakdown of the therapeutic protein to which it is attached, thereby extending the time that the protein is active in the body.
Recombinant factor IX is a serine protease involved in the coagulation process. Factor IX is activated by factor XIa or factor VIIa into factor IXa and in turn activates factor X to form factor Xa.
PROLOR and OPKO
In April 2013, OPKO and PROLOR announced that the companies signed a definitive merger agreement under which OPKO will acquire PROLOR in an all-stock transaction. Under the terms of the agreement holders of PROLOR common stock will receive 0.9951 shares of OPKO common stock for each share of PROLOR common stock. In August 2013, OPKO Health and PROLOR Biotech jointly announced the completion of the acquisition of PROLOR by OPKO.
Factor IX-CTP News
Additional information available to subscribers only: